Cellectar, Inc. Announces Initiation Of Phase 2 Imaging Trial With I-124-CLR1404 In Patients With Newly Diagnosed Or Recurrent Glioblastoma
MADISON, Wis., March 4, 2014 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (OTCQX:CLRB) a biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced enrollment of the first patient in its Phase II imaging trial of I-124-CLR1404 in patients with glioblastoma.
Help employers find you! Check out all the jobs and post your resume.